Evidence map›Paper›PMID 22211895›Full record

ReviewAnnals of the New York Academy of Sciences2011

Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications.

Ravichandran Ramasamy, Shi Fang Yan, Ann Marie Schmidt

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Annals of the New York Academy of Sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04183920 (To Determine the Activity and Mechanisms of Cranberries to Attenuate Skin Photoaging and Improve Skin Health in Women), which is not on this map. Cited by 258 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
258citing papers in PubMed, 3 pooled it
18.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04183920 nacompletednot on this mapstarted 2020, after this paper: background citation

To Determine the Activity and Mechanisms of Cranberries to Attenuate Skin Photoaging and Improve Skin Health in Women

TypeinterventionalSponsorUniversity of FloridaRan2020 to 2024Enrolled22ConditionsSkin HealthArmsCranberry juice, Placebo juice
3 · Its place in the literature

Who cites it

258 citing papers in PubMed, 3 syntheses or guidelines pooled it, 505 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Mechanism ofRenal failure · 2025
    Article
  19. Review
  20. Article

198 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ravichandran RamasamyDiabetes Research Program, Division of Endocrinology, Department of Medicine, New York University School of Medicine, New York, New York 10016, USA.
Shi Fang Yan
Ann Marie Schmidt
New York University · US

Funding

VASCULAR AND MONOCYTE DYSFUNCTION IN WOUND REPAIRP01HL060901 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI RAMASAMY, RAVICHANDRAN, SCHMIDT, ANN MARIE · 1999 to 2017
$20.2M
TRANSGENIC MOUSE AND ANIMAL MANAGEMENTP01AG026467 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SCHMIDT, ANN MARIE · 2008 to 2014
$9.2M
NHLBI NIH HHS P01 HL060901NIA NIH HHS P01 AG026467
6 · The paper itself

Abstract

The receptor for advanced glycation endproducts (RAGE) was first described as a signal transduction receptor for advanced glycation endproducts (AGEs), the products of nonenzymatic glycation and oxidation of proteins and lipids that accumulate in diabetes and in inflammatory foci. The discovery that RAGE was a receptor for inflammatory S100/calgranulins and high mobility group box 1 (HMGB1) set the stage for linking RAGE to both the consequences and causes of types 1 and 2 diabetes. Recent discoveries regarding the structure of RAGE as well as novel intracellular binding partner interactions advance our understanding of the mechanisms by which RAGE evokes pathological consequences and underscore strategies by which antagonism of RAGE in the clinic may be realized. Finally, recent data tracking RAGE in the clinic suggest that levels of soluble RAGEs and polymorphisms in the gene encoding RAGE may hold promise for the identification of patients who are vulnerable to the complications of diabetes and/or are receptive to therapeutic interventions designed to prevent and reverse the damage inflicted by chronic hyperglycemia, irrespective of its etiology.

Indexed as

AnimalsCardiovascular DiseasesCarrier ProteinsDiabetes ComplicationsDiabetes MellitusDiabetic NephropathiesForminsHumansInflammationMiceReceptor for Advanced Glycation End ProductsReceptors, ImmunologicSignal TransductionCarrier ProteinsDiap1 protein, mouseForminsReceptor for Advanced Glycation End ProductsReceptors, Immunologic

Identifiers

PMID22211895
PMCPMC4501013
OpenAlexW1598235393

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.